Samsung Bioepis secures Japan approval for its ustekinumab biosimilar with Nipro, marking a key step in Asia’s biosimilar adoption. Find out what this means.
Amgen has expanded its direct-to-patient program, AmgenNow, to include Aimovig (erenumab-aooe) and Amjevita (adalimumab-atto), each now available at a flat monthly price of $299 for eligible U.S. patients. This development forms part of Amgen’s broader agreement with the Trump Administration, satisfying conditions laid out in the President’s July 31 policy letter and positioning the company […]